{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,9]],"date-time":"2025-02-09T05:09:16Z","timestamp":1739077756178,"version":"3.37.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T00:00:00Z","timestamp":1736985600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T00:00:00Z","timestamp":1736985600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Ulm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Li-Fraumeni syndrome (LFS) is an autosomal dominant tumor predisposition syndrome characterized by a high familial incidence of various malignancies. It results from pathogenic\/likely pathogenic heterozygous constitutional variants of the <jats:italic>TP53<\/jats:italic> gene. Due to impaired DNA damage repair, conventional cytotoxic therapies or radiotherapy should be avoided whenever feasible to mitigate the high incidence of treatment-related secondary malignancies in these patients. However, there is limited evidence supporting the effectiveness of targeted therapy approaches in LFS patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Case presentation<\/jats:title>\n            <jats:p>We present the case of a woman with breast cancer and subsequent osteosarcoma, both treated with surgery and chemotherapy. Constitutional genetic germline testing identified a pathogenic <jats:italic>TP53<\/jats:italic> variant in line with the clinical features of Li-Fraumeni syndrome. Subsequent molecular analysis of the osteosarcoma tissue revealed homozygous loss of the <jats:italic>CDKN2A<\/jats:italic> gene locus, warranting treatment with CDK4\/6 inhibitor palbociclib. Palbociclib therapy was discontinued after one year with no evidence of disease. One year later, ovarian cancer was diagnosed, with molecular analysis indicating interstitial heterozygous loss of the <jats:italic>BRCA2<\/jats:italic> gene locus, providing a rationale for targeted therapy with the PARP inhibitor olaparib.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>In the era of accessible and comprehensive genetic and phenotypic tumor profiling, this case study of a patient with Li-Fraumeni syndrome underscores the success of precision oncology in harnessing additional somatic oncogenic driver alterations. Furthermore, it emphasizes the indispensable role of an interdisciplinary molecular tumor board, enhancing the awareness of molecular profiling and targeted therapies in patients with rare cancer susceptibility disorders.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00432-024-06077-7","type":"journal-article","created":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T06:08:14Z","timestamp":1737007694000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Exploiting somatic oncogenic driver alterations in a patient with Li-Fraumeni syndrome\u2013 paving the path towards precision medicine: a case report"],"prefix":"10.1007","volume":"151","author":[{"given":"Carolin","family":"Seeling","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonja","family":"Dahlum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralf","family":"Marienfeld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vera","family":"Jan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brigitte","family":"Rack","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uwe","family":"Gerstenmaier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ambros J.","family":"Beer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Regine","family":"Mayer-Steinacker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Thaiss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas F. E.","family":"Barth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Seufferlein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadine T.","family":"Gaisa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"Stilgenbauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Janni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reiner","family":"Siebert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hartmut","family":"D\u00f6hner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Verena I.","family":"Gaidzik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,16]]},"reference":[{"key":"6077_CR36","doi-asserted-by":"crossref","unstructured":"Alba-Pavon P, Alana L, Astigarraga I, Villate O (2022) Splicing-disrupting mutations in inherited predisposition to Solid Pediatric Cancer. Cancers (Basel).;14(23)","DOI":"10.3390\/cancers14235967"},{"issue":"12","key":"6077_CR53","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/S1470-2045(21)00531-3","volume":"22","author":"S Banerjee","year":"2021","unstructured":"Banerjee S, Moore KN, Colombo N, Scambia G, Kim BG, Oaknin A et al (2021) Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1\/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 22(12):1721\u20131731","journal-title":"Lancet Oncol"},{"issue":"2","key":"6077_CR32","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1016\/j.cllc.2019.11.012","volume":"21","author":"MVR Barbosa","year":"2020","unstructured":"Barbosa MVR, Cordeiro de Lima VC, Formiga MN, Andrade de Paula CA, Torrezan GT, Carraro DM (2020) High prevalence of EGFR mutations in lung adenocarcinomas from Brazilian patients harboring the TP53 p.R337H variant. Clin Lung Cancer 21(2):e37\u2013e44","journal-title":"Clin Lung Cancer"},{"key":"6077_CR12","doi-asserted-by":"crossref","first-page":"e2400139","DOI":"10.1200\/PO.24.00139","volume":"8","author":"M Bottosso","year":"2024","unstructured":"Bottosso M, Verret B, Caron O, Hamzaoui N, Pasmant E, Danlos FX et al (2024) Efficacy and safety of Immune Checkpoint Blockade in patients with Li-Fraumeni Syndrome. JCO Precis Oncol 8:e2400139","journal-title":"JCO Precis Oncol"},{"issue":"21","key":"6077_CR6","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1200\/JCO.2014.59.5728","volume":"33","author":"G Bougeard","year":"2015","unstructured":"Bougeard G, Renaux-Petel M, Flaman JM, Charbonnier C, Fermey P, Belotti M et al (2015) Revisiting Li-Fraumeni Syndrome from TP53 mutation carriers. J Clin Oncol 33(21):2345\u20132352","journal-title":"J Clin Oncol"},{"issue":"7035","key":"6077_CR55","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nature03443","volume":"434","author":"HE Bryant","year":"2005","unstructured":"Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E et al (2005) Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434(7035):913\u2013917","journal-title":"Nature"},{"key":"6077_CR30","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/978-94-017-9211-0_18","volume":"85","author":"AV Budanov","year":"2014","unstructured":"Budanov AV (2014) The role of tumor suppressor p53 in the antioxidant defense and metabolism. Subcell Biochem 85:337\u2013358","journal-title":"Subcell Biochem"},{"issue":"1","key":"6077_CR7","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1136\/jmg.38.1.43","volume":"38","author":"A Chompret","year":"2001","unstructured":"Chompret A, Abel A, Stoppa-Lyonnet D, Brugieres L, Pages S, Feunteun J, Bonaiti-Pellie C (2001) Sensitivity and predictive value of criteria for p53 germline mutation screening. J Med Genet 38(1):43\u201347","journal-title":"J Med Genet"},{"issue":"25","key":"6077_CR54","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1056\/NEJMoa1909707","volume":"381","author":"RL Coleman","year":"2019","unstructured":"Coleman RL, Fleming GF, Brady MF, Swisher EM, Steffensen KD, Friedlander M et al (2019) Veliparib with First-Line Chemotherapy and as maintenance therapy in Ovarian Cancer. N Engl J Med 381(25):2403\u20132415","journal-title":"N Engl J Med"},{"issue":"3","key":"6077_CR28","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/s41588-019-0576-7","volume":"52","author":"I Cortes-Ciriano","year":"2020","unstructured":"Cortes-Ciriano I, Lee JJ, Xi R, Jain D, Jung YL, Yang L et al (2020) Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing. Nat Genet 52(3):331\u2013341","journal-title":"Nat Genet"},{"issue":"12","key":"6077_CR3","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1016\/S1470-2045(21)00580-5","volume":"22","author":"KC de Andrade","year":"2021","unstructured":"de Andrade KC, Khincha PP, Hatton JN, Frone MN, Wegman-Ostrosky T, Mai PL et al (2021) Cancer incidence, patterns, and genotype-phenotype associations in individuals with pathogenic or likely pathogenic germline TP53 variants: an observational cohort study. Lancet Oncol 22(12):1787\u20131798","journal-title":"Lancet Oncol"},{"issue":"1","key":"6077_CR17","first-page":"100242","volume":"5","author":"KC de Andrade","year":"2024","unstructured":"de Andrade KC, Strande NT, Kim J, Haley JS, Hatton JN, Frone MN et al (2024) Genome-first approach of the prevalence and cancer phenotypes of pathogenic or likely pathogenic germline TP53 variants. HGG Adv 5(1):100242","journal-title":"HGG Adv"},{"issue":"1","key":"6077_CR37","doi-asserted-by":"crossref","first-page":"100283","DOI":"10.1016\/j.labinv.2023.100283","volume":"104","author":"V Difilippo","year":"2023","unstructured":"Difilippo V, Saba KH, Styring E, Magnusson L, Nilsson J, Nathrath M et al (2023) Osteosarcomas with few chromosomal alterations or adult onset are genetically heterogeneous. Lab Invest 104(1):100283","journal-title":"Lab Invest"},{"issue":"10","key":"6077_CR11","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1038\/s41431-020-0638-4","volume":"28","author":"T Frebourg","year":"2020","unstructured":"Frebourg T, Bajalica Lagercrantz S, Oliveira C, Magenheim R, Evans DG (2020) European Reference Network G. Guidelines for the Li-Fraumeni and heritable TP53-related cancer syndromes. Eur J Hum Genet 28(10):1379\u20131386","journal-title":"Eur J Hum Genet"},{"issue":"3","key":"6077_CR31","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s10549-018-05127-2","volume":"174","author":"A Friedlaender","year":"2019","unstructured":"Friedlaender A, Vuilleumier A, Viassolo V, Ayme A, De Talhouet S, Combes JD et al (2019) BRCA1\/BRCA2 germline mutations and chemotherapy-related hematological toxicity in breast cancer patients. Breast Cancer Res Treat 174(3):775\u2013783","journal-title":"Breast Cancer Res Treat"},{"issue":"8","key":"6077_CR18","doi-asserted-by":"crossref","first-page":"100875","DOI":"10.1016\/j.gim.2023.100875","volume":"25","author":"UA Friedrich","year":"2023","unstructured":"Friedrich UA, Bienias M, Zinke C, Prazenicova M, Lohse J, Jahn A et al (2023) A clinical screening tool to detect genetic cancer predisposition in pediatric oncology shows high sensitivity but can miss a substantial percentage of affected children. Genet Med 25(8):100875","journal-title":"Genet Med"},{"issue":"1","key":"6077_CR29","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1093\/carcin\/bgs318","volume":"34","author":"I Goldstein","year":"2013","unstructured":"Goldstein I, Rivlin N, Shoshana OY, Ezra O, Madar S, Goldfinger N, Rotter V (2013) Chemotherapeutic agents induce the expression and activity of their clearing enzyme CYP3A4 by activating p53. Carcinogenesis 34(1):190\u2013198","journal-title":"Carcinogenesis"},{"key":"6077_CR16","doi-asserted-by":"crossref","unstructured":"Guha T, Malkin D (2017) Inherited TP53 mutations and the Li-Fraumeni Syndrome. Cold Spring Harb Perspect Med.;7(4)","DOI":"10.1101\/cshperspect.a026187"},{"issue":"1","key":"6077_CR50","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1186\/s12964-024-01580-3","volume":"22","author":"X Guo","year":"2024","unstructured":"Guo X, Yang Y, Tang J, Xiang J (2024) Ephs in cancer progression: complexity and context-dependent nature in signaling, angiogenesis and immunity. Cell Commun Signal 22(1):299","journal-title":"Cell Commun Signal"},{"issue":"21","key":"6077_CR24","doi-asserted-by":"crossref","first-page":"7954","DOI":"10.1002\/cam4.3427","volume":"9","author":"PG Hendrickson","year":"2020","unstructured":"Hendrickson PG, Luo Y, Kohlmann W, Schiffman J, Maese L, Bishop AJ et al (2020) Radiation therapy and secondary malignancy in Li-Fraumeni syndrome: a hereditary cancer registry study. Cancer Med 9(21):7954\u20137963","journal-title":"Cancer Med"},{"key":"6077_CR49","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/1471-2407-6-144","volume":"6","author":"NI Herath","year":"2006","unstructured":"Herath NI, Spanevello MD, Sabesan S, Newton T, Cummings M, Duffy S et al (2006) Over-expression of Eph and ephrin genes in advanced ovarian cancer: ephrin gene expression correlates with shortened survival. BMC Cancer 6:144","journal-title":"BMC Cancer"},{"key":"6077_CR25","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/1748-717X-5-104","volume":"5","author":"S Heymann","year":"2010","unstructured":"Heymann S, Delaloge S, Rahal A, Caron O, Frebourg T, Barreau L et al (2010) Radio-induced malignancies after breast cancer postoperative radiotherapy in patients with Li-Fraumeni syndrome. Radiat Oncol 5:104","journal-title":"Radiat Oncol"},{"issue":"11","key":"6077_CR61","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1158\/2159-8290.CD-21-0126","volume":"11","author":"P Horak","year":"2021","unstructured":"Horak P, Heining C, Kreutzfeldt S, Hutter B, Mock A, Hullein J et al (2021) Comprehensive genomic and transcriptomic analysis for guiding therapeutic decisions in patients with rare cancers. Cancer Discov 11(11):2780\u20132795","journal-title":"Cancer Discov"},{"issue":"1","key":"6077_CR14","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s13045-021-01169-0","volume":"14","author":"J Hu","year":"2021","unstructured":"Hu J, Cao J, Topatana W, Juengpanich S, Li S, Zhang B et al (2021) Targeting mutant p53 for cancer therapy: direct and indirect strategies. J Hematol Oncol 14(1):157","journal-title":"J Hematol Oncol"},{"issue":"1","key":"6077_CR44","doi-asserted-by":"crossref","first-page":"7207","DOI":"10.1038\/s41467-022-34689-5","volume":"13","author":"Y Jiang","year":"2022","unstructured":"Jiang Y, Wang J, Sun M, Zuo D, Wang H, Shen J et al (2022) Multi-omics analysis identifies osteosarcoma subtypes with distinct prognosis indicating stratified treatment. Nat Commun 13(1):7207","journal-title":"Nat Commun"},{"issue":"6","key":"6077_CR47","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1158\/1541-7786.MCR-14-0660-T","volume":"13","author":"KR Kampen","year":"2015","unstructured":"Kampen KR, Scherpen FJ, Garcia-Manero G, Yang H, Kaspers GJ, Cloos J et al (2015) EphB1 suppression in Acute Myelogenous Leukemia: regulating the DNA damage control system. Mol Cancer Res 13(6):982\u2013992","journal-title":"Mol Cancer Res"},{"key":"6077_CR26","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.ejca.2018.06.011","volume":"101","author":"E Kasper","year":"2018","unstructured":"Kasper E, Angot E, Colasse E, Nicol L, Sabourin JC, Adriouch S et al (2018) Contribution of genotoxic anticancer treatments to the development of multiple primary tumours in the context of germline TP53 mutations. Eur J Cancer 101:254\u2013262","journal-title":"Eur J Cancer"},{"issue":"1","key":"6077_CR57","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.1038\/s41467-020-17127-2","volume":"11","author":"H Kim","year":"2020","unstructured":"Kim H, Xu H, George E, Hallberg D, Kumar S, Jagannathan V et al (2020) Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models. Nat Commun 11(1):3726","journal-title":"Nat Commun"},{"issue":"12","key":"6077_CR8","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1007\/s10147-021-02011-w","volume":"26","author":"T Kumamoto","year":"2021","unstructured":"Kumamoto T, Yamazaki F, Nakano Y, Tamura C, Tashiro S, Hattori H et al (2021) Medical guidelines for Li-Fraumeni syndrome 2019, version 1.1. Int J Clin Oncol 26(12):2161\u20132178","journal-title":"Int J Clin Oncol"},{"issue":"3","key":"6077_CR60","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.jamcollsurg.2013.04.035","volume":"217","author":"BW Lamb","year":"2013","unstructured":"Lamb BW, Green JS, Benn J, Brown KF, Vincent CA, Sevdalis N (2013) Improving decision making in multidisciplinary tumor boards: prospective longitudinal evaluation of a multicomponent intervention for 1,421 patients. J Am Coll Surg 217(3):412\u2013420","journal-title":"J Am Coll Surg"},{"key":"6077_CR20","unstructured":"Lavoie JM, Csizmok V, Williamson LM, Culibrk L, Wang G, Marra MA et al (2022) Whole-genome and transcriptome analysis of advanced adrenocortical cancer highlights multiple alterations affecting epigenome and DNA repair pathways. Cold Spring Harb Mol Case Stud.;8(3)"},{"issue":"6","key":"6077_CR1","first-page":"1365","volume":"43","author":"FP Li","year":"1969","unstructured":"Li FP, Fraumeni JF Jr (1969) Rhabdomyosarcoma in children: epidemiologic study and identification of a familial cancer syndrome. J Natl Cancer Inst 43(6):1365\u20131373","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"6077_CR39","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.3390\/ijms16022294","volume":"16","author":"Z Li","year":"2015","unstructured":"Li Z, Xiao J, Hu K, Wang G, Li M, Zhang J, Cheng G (2015) FBXW7 acts as an independent prognostic marker and inhibits tumor growth in human osteosarcoma. Int J Mol Sci 16(2):2294\u20132306","journal-title":"Int J Mol Sci"},{"issue":"2","key":"6077_CR46","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1073\/pnas.1814027116","volume":"116","author":"C Li","year":"2019","unstructured":"Li C, Bonazzoli E, Bellone S, Choi J, Dong W, Menderes G et al (2019) Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors. Proc Natl Acad Sci U S A 116(2):619\u2013624","journal-title":"Proc Natl Acad Sci U S A"},{"key":"6077_CR51","doi-asserted-by":"crossref","unstructured":"Li S, Wang T, Fei X, Zhang M (2022) ATR inhibitors in platinum-resistant ovarian Cancer. Cancers (Basel).;14(23)","DOI":"10.3390\/cancers14235902"},{"issue":"1","key":"6077_CR35","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/s41467-022-35727-y","volume":"14","author":"N Light","year":"2023","unstructured":"Light N, Layeghifard M, Attery A, Subasri V, Zatzman M, Anderson ND et al (2023) Germline TP53 mutations undergo copy number gain years prior to tumor diagnosis. Nat Commun 14(1):77","journal-title":"Nat Commun"},{"issue":"11","key":"6077_CR34","doi-asserted-by":"crossref","first-page":"6009","DOI":"10.1128\/MCB.16.11.6009","volume":"16","author":"JH Ludes-Meyers","year":"1996","unstructured":"Ludes-Meyers JH, Subler MA, Shivakumar CV, Munoz RM, Jiang P, Bigger JE et al (1996) Transcriptional activation of the human epidermal growth factor receptor promoter by human p53. Mol Cell Biol 16(11):6009\u20136019","journal-title":"Mol Cell Biol"},{"issue":"5","key":"6077_CR63","first-page":"462","volume":"65","author":"E Mack","year":"2024","unstructured":"Mack E, Horak P, Frohling S, Neubauer A (2024) [Precision oncology and molecular tumor boards]. Inn Med (Heidelb) 65(5):462\u2013471","journal-title":"Inn Med (Heidelb)"},{"issue":"23","key":"6077_CR2","doi-asserted-by":"crossref","first-page":"3673","DOI":"10.1002\/cncr.30248","volume":"122","author":"PL Mai","year":"2016","unstructured":"Mai PL, Best AF, Peters JA, DeCastro RM, Khincha PP, Loud JT et al (2016) Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort. Cancer 122(23):3673\u20133681","journal-title":"Cancer"},{"issue":"7","key":"6077_CR13","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1016\/j.jtho.2020.03.005","volume":"15","author":"L Mezquita","year":"2020","unstructured":"Mezquita L, Jove M, Nadal E, Kfoury M, Moran T, Ricordel C et al (2020) High prevalence of somatic oncogenic driver alterations in patients with NSCLC and Li-Fraumeni Syndrome. J Thorac Oncol 15(7):1232\u20131239","journal-title":"J Thorac Oncol"},{"issue":"9","key":"6077_CR33","first-page":"2892","volume":"5","author":"A Midha","year":"2015","unstructured":"Midha A, Dearden S, McCormack R (2015) EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). Am J Cancer Res 5(9):2892\u20132911","journal-title":"Am J Cancer Res"},{"issue":"1","key":"6077_CR62","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41698-023-00458-w","volume":"7","author":"A Mock","year":"2023","unstructured":"Mock A, Teleanu MV, Kreutzfeldt S, Heilig CE, Hullein J, Mohrmann L et al (2023) NCT\/DKFZ MASTER handbook of interpreting whole-genome, transcriptome, and methylome data for precision oncology. NPJ Precis Oncol 7(1):109","journal-title":"NPJ Precis Oncol"},{"issue":"4","key":"6077_CR21","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1002\/path.1848","volume":"207","author":"Y Oda","year":"2005","unstructured":"Oda Y, Yamamoto H, Takahira T, Kobayashi C, Kawaguchi K, Tateishi N et al (2005) Frequent alteration of p16(INK4a)\/p14(ARF) and p53 pathways in the round cell component of myxoid\/round cell liposarcoma: p53 gene alterations and reduced p14(ARF) expression both correlate with poor prognosis. J Pathol 207(4):410\u2013421","journal-title":"J Pathol"},{"issue":"1","key":"6077_CR41","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12943-018-0779-z","volume":"17","author":"S Pal Singh","year":"2018","unstructured":"Pal Singh S, Dammeijer F, Hendriks RW (2018) Role of Bruton\u2019s tyrosine kinase in B cells and malignancies. Mol Cancer 17(1):57","journal-title":"Mol Cancer"},{"issue":"1","key":"6077_CR45","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s13045-022-01344-x","volume":"15","author":"HE Persha","year":"2022","unstructured":"Persha HE, Kato S, De P, Adashek JJ, Sicklick JK, Subbiah V, Kurzrock R (2022) Osteosarcoma with cell-cycle and fibroblast growth factor genomic alterations: case report of Molecular Tumor Board combination strategy resulting in long-term exceptional response. J Hematol Oncol 15(1):119","journal-title":"J Hematol Oncol"},{"issue":"63","key":"6077_CR42","doi-asserted-by":"crossref","first-page":"106639","DOI":"10.18632\/oncotarget.22543","volume":"8","author":"M Rada","year":"2017","unstructured":"Rada M, Althubiti M, Ekpenyong-Akiba AE, Lee KG, Lam KP, Fedorova O et al (2017) BTK blocks the inhibitory effects of MDM2 on p53 activity. Oncotarget 8(63):106639\u2013106647","journal-title":"Oncotarget"},{"issue":"11","key":"6077_CR5","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1038\/s41436-019-0541-y","volume":"21","author":"HQ Rana","year":"2019","unstructured":"Rana HQ, Clifford J, Hoang L, LaDuca H, Black MH, Li S et al (2019) Genotype-phenotype associations among panel-based TP53\u2009+\u2009subjects. Genet Med 21(11):2478\u20132484","journal-title":"Genet Med"},{"issue":"1\u20132","key":"6077_CR27","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.cell.2011.12.013","volume":"148","author":"T Rausch","year":"2012","unstructured":"Rausch T, Jones DT, Zapatka M, Stutz AM, Zichner T, Weischenfeldt J et al (2012) Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. Cell 148(1\u20132):59\u201371","journal-title":"Cell"},{"issue":"5","key":"6077_CR15","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J et al (2015) Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 17(5):405\u2013424","journal-title":"Genet Med"},{"issue":"6","key":"6077_CR19","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1136\/jmg.2009.073429","volume":"47","author":"MW Ruijs","year":"2010","unstructured":"Ruijs MW, Verhoef S, Rookus MA, Pruntel R, van der Hout AH, Hogervorst FB et al (2010) TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes. J Med Genet 47(6):421\u2013428","journal-title":"J Med Genet"},{"issue":"2","key":"6077_CR56","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.ygyno.2021.08.024","volume":"163","author":"PD Shah","year":"2021","unstructured":"Shah PD, Wethington SL, Pagan C, Latif N, Tanyi J, Martin LP et al (2021) Combination ATR and PARP inhibitor (CAPRI): a phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer. Gynecol Oncol 163(2):246\u2013253","journal-title":"Gynecol Oncol"},{"issue":"24","key":"6077_CR40","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1182\/blood.2021012315","volume":"138","author":"M Sivina","year":"2021","unstructured":"Sivina M, Kim E, Wierda WG, Ferrajoli A, Jain N, Thompson P et al (2021) Ibrutinib induces durable remissions in treatment-naive patients with CLL and 17p deletion and\/or TP53 mutations. Blood 138(24):2589\u20132592","journal-title":"Blood"},{"issue":"1","key":"6077_CR59","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s12913-020-4930-3","volume":"20","author":"ML Specchia","year":"2020","unstructured":"Specchia ML, Frisicale EM, Carini E, Di Pilla A, Cappa D, Barbara A et al (2020) The impact of tumor board on cancer care: evidence from an umbrella review. BMC Health Serv Res 20(1):73","journal-title":"BMC Health Serv Res"},{"key":"6077_CR43","doi-asserted-by":"crossref","unstructured":"Szklener K, Michalski A, Zak K, Piwonski M, Mandziuk S (2022) Ibrutinib in the treatment of solid tumors: current state of knowledge and future directions. Cells.;11(8)","DOI":"10.3390\/cells11081338"},{"issue":"2","key":"6077_CR58","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/s43018-022-00332-x","volume":"3","author":"D Tamborero","year":"2022","unstructured":"Tamborero D, Dienstmann R, Rachid MH, Boekel J, Lopez-Fernandez A, Jonsson M et al (2022) The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology. Nat Cancer 3(2):251\u2013261","journal-title":"Nat Cancer"},{"issue":"6","key":"6077_CR10","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S1470-2045(11)70119-X","volume":"12","author":"A Villani","year":"2011","unstructured":"Villani A, Tabori U, Schiffman J, Shlien A, Beyene J, Druker H et al (2011) Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study. Lancet Oncol 12(6):559\u2013567","journal-title":"Lancet Oncol"},{"issue":"9","key":"6077_CR9","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/S1470-2045(16)30249-2","volume":"17","author":"A Villani","year":"2016","unstructured":"Villani A, Shore A, Wasserman JD, Stephens D, Kim RH, Druker H et al (2016) Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study. Lancet Oncol 17(9):1295\u20131305","journal-title":"Lancet Oncol"},{"issue":"1","key":"6077_CR48","first-page":"313","volume":"7","author":"H Wang","year":"2014","unstructured":"Wang H, Wen J, Wang H, Guo Q, Shi S, Shi Q et al (2014) Loss of expression of EphB1 protein in serous carcinoma of ovary associated with metastasis and poor survival. Int J Clin Exp Pathol 7(1):313\u2013321","journal-title":"Int J Clin Exp Pathol"},{"issue":"5","key":"6077_CR23","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/ng.2938","volume":"46","author":"G Wu","year":"2014","unstructured":"Wu G, Diaz AK, Paugh BS, Rankin SL, Ju B, Li Y et al (2014) The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma. Nat Genet 46(5):444\u2013450","journal-title":"Nat Genet"},{"issue":"1","key":"6077_CR38","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41698-024-00627-5","volume":"8","author":"D Xu","year":"2024","unstructured":"Xu D, Yin S, Shu Y (2024) NF2: an underestimated player in cancer metabolic reprogramming and tumor immunity. NPJ Precis Oncol 8(1):133","journal-title":"NPJ Precis Oncol"},{"issue":"27","key":"6077_CR52","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.1200\/JCO.19.02404","volume":"38","author":"TA Yap","year":"2020","unstructured":"Yap TA, O\u2019Carrigan B, Penney MS, Lim JS, Brown JS, de Miguel Luken MJ et al (2020) Phase I Trial of First-in-class ATR inhibitor M6620 (VX-970) as Monotherapy or in combination with carboplatin in patients with Advanced Solid tumors. J Clin Oncol 38(27):3195\u20133204","journal-title":"J Clin Oncol"},{"issue":"6","key":"6077_CR22","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nm.4333","volume":"23","author":"A Zehir","year":"2017","unstructured":"Zehir A, Benayed R, Shah RH, Syed A, Middha S, Kim HR et al (2017) Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med 23(6):703\u2013713","journal-title":"Nat Med"},{"issue":"10","key":"6077_CR4","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.tips.2017.07.004","volume":"38","author":"R Zhou","year":"2017","unstructured":"Zhou R, Xu A, Gingold J, Strong LC, Zhao R, Lee DF (2017) Li-Fraumeni Syndrome Disease Model: a platform to develop Precision Cancer Therapy Targeting Oncogenic p53. Trends Pharmacol Sci 38(10):908\u2013927","journal-title":"Trends Pharmacol Sci"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-024-06077-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-024-06077-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-024-06077-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T07:17:16Z","timestamp":1738999036000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-024-06077-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,16]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["6077"],"URL":"https:\/\/doi.org\/10.1007\/s00432-024-06077-7","relation":{},"ISSN":["1432-1335"],"issn-type":[{"type":"electronic","value":"1432-1335"}],"subject":[],"published":{"date-parts":[[2025,1,16]]},"assertion":[{"value":"30 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This case report was carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki). Written informed consent was obtained from the patient before submission of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent for publication of the patient clinical details and results of the molecular analysis were obtained from the patient.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"37"}}